Delayed severe abciximab-induced thrombocytopenia: A case report

Thrombocytopenia is a possible side effect of routinely administered medical agents widely used in the management of patients with acute coronary syndromes (ACS). It is usually observed within 24 h after abciximab infusion. Differential diagnosis is challenging and the management controversial.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research